Education
About Us
Working with TipRanks
Follow Us
Monopar Therapeutics Inc (MNPR)
NASDAQ:MNPR
RESEARCH TOOLSreports
Total Valuation
Monopar Therapeutics Inc has a market cap or net worth of $262.60M. The enterprise value is $27.22M.
Market Cap$262.60M
Enterprise Value$27.22M
Share Statistics
Monopar Therapeutics Inc has 6,112,593 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,112,593
Owned by Insiders16.92%
Owned by Institutions20.42%
Financial Efficiency
Monopar Therapeutics Inc’s return on equity (ROE) is -1.50 and return on invested capital (ROIC) is -158.05%.
Return on Equity (ROE)-1.50
Return on Assets (ROA)-1.14
Return on Invested Capital (ROIC)-158.05%
Return on Capital Employed (ROCE)-1.58
Revenue Per Employee0.00
Profits Per Employee-600.16K
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Monopar Therapeutics Inc is -2.94. Monopar Therapeutics Inc’s PEG ratio is 0.10.
PE Ratio-2.94
PS Ratio―
PB Ratio4.41
Price to Fair Value4.41
Price to FCF-3.14
Price to Operating Cash Flow-3.14
PEG Ratio0.10
Income Statement
In the last 12 months, Monopar Therapeutics Inc had revenue of 0.00 and earned -8.40M in profits. Earnings per share was -0.58.
Revenue0.00
Gross Profit0.00
Operating Income-8.83M
Pretax Income-8.40M
Net Income-8.40M
EBITDA429.04K
Earnings Per Share (EPS)-0.58
Cash Flow
In the last 12 months, operating cash flow was -4.88M and capital expenditures -2.00, giving a free cash flow of -5.95M billion.
Operating Cash Flow-4.88M
Free Cash Flow-5.95M
Free Cash Flow per Share-0.97
Dividends & Yields
Monopar Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.47
52-Week Price Change1220.70%
50-Day Moving Average36.43
200-Day Moving Average20.05
Relative Strength Index (RSI)58.49
Average Volume (3m)27.95K
Important Dates
Monopar Therapeutics Inc upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateMar 31, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Monopar Therapeutics Inc as a current ratio of 4.17, with Debt / Equity ratio of 0.00%
Current Ratio4.17
Quick Ratio4.17
Debt to Market Cap0.00
Net Debt to EBITDA-16.94
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Monopar Therapeutics Inc has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Monopar Therapeutics Inc EV to EBITDA ratio is 40.56, with an EV/FCF ratio of -2.21.
EV to Sales0.00
EV to EBITDA40.56
EV to Free Cash Flow-2.21
EV to Operating Cash Flow-2.21
Balance Sheet
Monopar Therapeutics Inc has $6.02M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$6.02M billion.
Cash & Marketable Securities$6.02M
Total Debt$0.00
Net Cash-$6.02M
Net Cash Per Share-$0.98
Tangible Book Value Per Share$0.39
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Monopar Therapeutics Inc is $52.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$52.00
Price Target Upside25.39% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast-35.23%